ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today its expanded and fully integrated portfolio of resuscitation and acute critical care technologies and data management solutions will be on display during the American Heart Association (AHA) 2017 Annual Conference in Booth 1839, November 12-14, in Anaheim, California. Nineteen presentations related to ZOLL technologies are scheduled to be presented during the AHA Resuscitation Science Symposium (ReSS).
ZOLL’s R Series® monitor/defibrillator offers continual waveform capnography, which is an American Heart Association (AHA) Class I recommendation for monitoring ET tube placement. It is the only defibrillator to offer both mainstream and sidestream capnography on one device. The R Series utilizes two proprietary technologies, Real CPR Help® and See-Thru CPR®, to help clinical staff consistently deliver high-quality CPR with minimal pause time. The R Series also provides an intuitive post-event data management software program to assist with critical quality improvements.
Unsurpassed CPR Support
Increasing the quality of CPR has been an ongoing commitment of ZOLL’s since 2002, when it was the first to introduce real-time CPR feedback in its AED Plus®. Today, all ZOLL defibrillators, including the AED Plus, the AED Pro®, the R Series, and the X Series® feature Real CPR Help audio and visual feedback for the correct depth, rate, release, and tracking of idle time. Real CPR Help is the only CPR feedback technology that, in combination with training, has been shown to impact survival to discharge, as demonstrated in published research.1
ZOLL’s commitment to high-quality CPR is also evident in the company’s suite of tools for optimal resuscitation response, which includes See-Thru CPR as well as EtCO2 monitoring. ZOLL’s proprietary See-Thru CPR technology, which minimizes the duration of pauses in CPR by enabling rescuers to see a patient’s organized underlying rhythm, is available on the R Series, the X Series, and the AED Pro.
Unmatched Pediatric Capabilities
ZOLL’s OneStep™ pediatric CPR electrodes are used in a majority of the top 25 US News and World Report pediatric cardiology hospitals. These are the only electrodes on the market with built-in CPR sensors that display the depth and rate of chest compressions during CPR on young children up to 8 years of age. These one-of-a-kind electrodes provide optimal support for pediatric resuscitation when paired with the ZOLL R Series or X Series. The OneStep pediatric CPR electrodes can be used for monitoring, pacing, and defibrillation, as well as displaying CPR quality on the R Series and X Series CPR Dashboard™.
AHA Guidelines Compliant
The 2015 AHA Guidelines recommend automated CPR devices, such as the AutoPulse® Resuscitation System, as Class IIb, citing their role in performing high-quality CPR when manual CPR is difficult to achieve, such as during patient transport or in the catheterization lab.
Enhanced Perfusion during CPR
To help enhance perfusion during CPR, ZOLL offers the ResQPOD® ITD* (impedance threshold device). Placed on an airway, the ResQPOD helps to enhance blood flow to the heart and brain during CPR and has been shown in clinical studies to increase survival from cardiac arrest by 25% or more.2
Targeted Temperature Management
ZOLL’s Thermogard XP® (TGXP) intravascular temperature management system provides health care professionals with the power and control needed to rapidly, safely, and accurately manage the core body temperature of critically ill or surgical patients with warming and cooling applications. It offers superior clinical efficiency in reaching and maintaining target temperature 100% of the time, 3-8 while decreasing demands on nursing staff and reducing nursing workload by 74%.9
New to the ZOLL portfolio is the Hospital Wearable Defibrillator (HWD), which was recently granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA). The ZOLL HWD is specifically designed to continuously protect patients at risk of ventricular tachycardia or ventricular fibrillation (VT/VF) during their hospital stay. For a patient experiencing VT/VF, each minute that defibrillation is delayed increases the likelihood of dying or the likelihood of surviving with complications.10
Also unique to ZOLL is the LifeVest® wearable defibrillator, which is worn by patients at risk for sudden cardiac death (SCD), providing protection during their changing condition and while permanent SCD risk has not been established. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest is lightweight and easy to wear and allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
Easy-to-Use Portable Ventilators
ZOLL’s Eagle II™ portable ventilator is designed to provide easy-to-use, effective ventilation, both during hospital transport and in the MRI suite. At less than 10 lbs. and offering multiple modes of ventilation, combined with ZOLL’s unique Smart Help™ technology, ZOLL ventilators are the ideal solution to provide ventilation therapy when transporting patients.
Scientific Assembly Presentations
An education grant from ZOLL helps to underwrite the AHA Resuscitation Science Symposium (ReSS), an international forum for scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury. Nineteen scientific presentations related to ZOLL products and technology are scheduled to be presented during ReSS. Key presentations are:
• Joshua Gaither will present Poster 158,“Comparison of Manual vs. Mechanical Chest Compression Quality during Prehospital Resuscitation,” on Saturday, November 11, 1:15-1:25 pm. PT in 155-159 ACC North.
• Raul J. Gazmuri will present Poster 163,“Defibrillation Guided by Real-time Ventricular Fibrillation Amplitude Spectral Area Analysis Outperforms Guidelines-driven Defibrillation during CPR in Swine,” on Saturday, November 11, 1:15-1:25 pm. PT in 155-159 ACC North.
• Tifany Hoyne will present Poster R155,“The Impact of Real-time Chest Compression Feedback Increases with Application of the 2015 Guidelines,” on Saturday, November 11, 1:45-1:55 pm. PT in 155-159 ACC North.
• Victor A. Convertino will present Poster R130,“Use of Intrathoracic Pressure Regulation Therapy in Breathing Patients for the Treatment of Hypotension Secondary to Trauma,” on Saturday, November 11, 1:55-2:05 pm. PT in 155-159 ACC North.
• Estaban Lopez-de-Sa will present Oral 07,“One-year Results of the Finding the Optimal Cooling Temperature after Out-of-hospital Cardiac Arrest Trial. FROST-I Pilot Trial,” on Saturday, November 11, 4:30-5:30 pm. PT in 154-158 ACC North.
• Dana E. Niles will present Poster 208,“Landscape of In-hospital CPR Quality Metrics across an International Pediatric Resuscitation Collaborative,” on Sunday, November 12, 8:10-8:20 am. PT in 155-159 ACC North.
• Johanna C. Moore will present Oral 9,“Head and Thorax Elevation during Cardiopulmonary Resuscitation Improves Cerebral Perfusion in a Swine Model of Prolonged Cardiac Arrest,” on Sunday, November 12, 10:45-11:00 am. PT in 151 ACC North.
• Tsuyoshi Masuda will present M3273,“Ambulatory Recordings of Cardiac Acoustic Biomarkers Demonstrate Early Recovery of Diastolic Function,” Monday, November 13, at 12:45-2:00 pm. PT in the Clinical Section, Science and Technology Hall.
A listing and schedule of the ZOLL-related presentations is available at zoll.com/aha-presentations-2017.
About ZOLL Medical Corporation
ZOLL Medical Corporation (zoll.com), an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care.
About Asahi Kasei
The Asahi Kasei Group (asahi-kasei.co.jp) is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries.
1. Bobrow BJ, et al. Ann Emerg Med. 2013 Jul;62(1):47 56.e1. Epub 2013 Mar 7.
2. Idris AH et al. Circulation. 2012; AHA Ress abstract #LBRS-352.
3. Hoedemaekers CW, et al. Critical Care. 2007;11:R91.
4. Knapik P, et al. Kardiologia Polska. 2011;69(11):1157-63.
5. Mayer SA, et al. Critical Care Medicine. 2004;(3)212:2508-15.
6. Diringer MN, et al. Critical Care Medicine. 2004;(32)2:559-564.
7. Heard KJ, et al. Resuscitation. 2010;81:9-14.
8. Horn CM, et al. Journal of Neurointerventional Surgery. 2014 Mar;6(2):91-95.
9. Icerea Deye N, et al. Circulation. 2015;132:182-193.
10. Larsen MP, et al. Ann Emerg Med. 1993;22: 1652 58.
Copyright © 2017 ZOLL Medical Corporation. All rights reserved. AED Plus, AED Pro, AutoPulse, CPR Dashboard, Eagle II, LifeVest, OneStep, Real CPR Help, ResQPOD, R Series, See-Thru CPR, Smart Help, Thermogard XP, X Series, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.